Redeye has today released an updated research report on LIDDS covering its expanded portfolio that now also includes a project targeting Toll-like Receptors (TLR).
The updated research report examines the development of Toll-like Receptors and the current market looking specifically at TLR9, the focus for LIDDS TLR research. The report also includes an update on Phase IIB Liproca Depot Study.
The updated research report is available at: https://www.redeye.se/company/lidds
Monica Wallter, CEO, will present LIDDS at the Redeye Investor After Work in Gothenburg on 25 April 2019.
For more information, please contact:
Monica Wallter, CEO, +46 (0)737 07 09 22, monica.wallter@liddspharma.com
LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology: NanoZolid®. NanoZolid is clinically validated drug development technology and superior in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid is combined with antiandrogens and in-house development projects in clinical and preclinical phase for cytostatics and immunoactive agents. LIDDS shares (LIDDS) are listed on Nasdaq First North. Redeye AB, Certifiedadviser@redeye.se, +46 (0)8 121 576 90, is a certified adviser to LIDDS. For more information, please visit liddspharma.com
—
This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: LIDDS AB via Globenewswire